12:00 AM
 | 
Aug 20, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Glivec imatinib regulatory update

Novartis withdrew an NDA for imatinib to treat pulmonary arterial hypertension (PAH) after FDA told the company additional data would be needed to support approval. The agency subsequently cancelled the Sept. 14 meeting of the Renal Drugs Advisory Committee, which had...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >